MX2023000881A - Estructura genomica del virus de la influenza. - Google Patents

Estructura genomica del virus de la influenza.

Info

Publication number
MX2023000881A
MX2023000881A MX2023000881A MX2023000881A MX2023000881A MX 2023000881 A MX2023000881 A MX 2023000881A MX 2023000881 A MX2023000881 A MX 2023000881A MX 2023000881 A MX2023000881 A MX 2023000881A MX 2023000881 A MX2023000881 A MX 2023000881A
Authority
MX
Mexico
Prior art keywords
influenza virus
mammal
provides
virus backbone
eliciting
Prior art date
Application number
MX2023000881A
Other languages
English (en)
Inventor
Pamuk Bilsel
Michael J Moser
Yasuko Hatta
Lindsay Hill-Batorski
Original Assignee
Flugen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flugen Inc filed Critical Flugen Inc
Publication of MX2023000881A publication Critical patent/MX2023000881A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención proporciona un virus de la influenza que tiene un crecimiento mejorado en las células Vero. El virus de la influenza incluye los segmentos génicos PA, NP y NS que tienen nucleótidos seleccionados y que codifican proteínas que tienen secuencias de aminoácidos con los aminoácidos seleccionados. La invención también proporciona una formulación farmacéutica que contiene el virus de la influenza, así como un método para provocar una respuesta inmune en un mamífero, administrando el virus de la influenza al mamífero, y un método para generar el virus de la influenza.
MX2023000881A 2020-07-21 2021-07-21 Estructura genomica del virus de la influenza. MX2023000881A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063054676P 2020-07-21 2020-07-21
PCT/US2021/042572 WO2022020469A1 (en) 2020-07-21 2021-07-21 Influenza virus backbone

Publications (1)

Publication Number Publication Date
MX2023000881A true MX2023000881A (es) 2023-02-22

Family

ID=79728941

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000881A MX2023000881A (es) 2020-07-21 2021-07-21 Estructura genomica del virus de la influenza.

Country Status (9)

Country Link
US (1) US20230295582A1 (es)
EP (1) EP4185601A1 (es)
JP (1) JP2023534839A (es)
KR (1) KR20230041775A (es)
CN (1) CN116134137A (es)
AU (1) AU2021311606A1 (es)
CA (1) CA3186401A1 (es)
MX (1) MX2023000881A (es)
WO (1) WO2022020469A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0613977D0 (en) * 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
US9284533B2 (en) 2011-06-24 2016-03-15 Flugen, Inc. Influenza virus mutants and uses therefor
AU2017221444B2 (en) * 2016-02-19 2021-07-29 Wisconsin Alumni Research Foundation (Warf) Improved influenza B virus replication for vaccine development

Also Published As

Publication number Publication date
EP4185601A1 (en) 2023-05-31
US20230295582A1 (en) 2023-09-21
AU2021311606A1 (en) 2023-02-09
KR20230041775A (ko) 2023-03-24
CA3186401A1 (en) 2022-01-27
CN116134137A (zh) 2023-05-16
JP2023534839A (ja) 2023-08-14
WO2022020469A1 (en) 2022-01-27

Similar Documents

Publication Publication Date Title
Magini et al. Self-amplifying mRNA vaccines expressing multiple conserved influenza antigens confer protection against homologous and heterosubtypic viral challenge
Hekele et al. Rapidly produced SAM® vaccine against H7N9 influenza is immunogenic in mice
JP2022066209A (ja) Ｍｄｃｋ、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス
WO2021159130A3 (en) Coronavirus rna vaccines and methods of use
MX2022009429A (es) Composiciones para la inmunizacion contra virus respiratorios.
CY1120622T1 (el) Μεθοδοι και συνθεσεις για επαγωγη μιας ανοσιακης αποκρισης ως προς egfrviii
MX2019004913A (es) Vacunas de nanoparticulas lipidicas que comprenden acido ribonucleico mensajero (arnm).
EP3452086A1 (en) Influenza mrna vaccines
MX2014004214A (es) Moleculas de acido ribonucleico policistronicas auto-replicantes recombinantes.
MX352974B (es) Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso.
HRP20180282T1 (hr) Imunoterapija na bazi indoleamin 2, 3-dioksigenaze
EA201891712A3 (ru) Молекулы нуклеиновых кислот гриппа и вакцины, изготовленные из них
BRPI0815578B8 (pt) peptídeos, agentes farmacêuticos compreendendo os mesmos, métodos in vitro para induzir uma célula apresentadora de antígeno, usos dos referidos peptídeos, e vacina
WO2008014521A3 (en) Improved vaccines and methods for using the same
MX343830B (es) Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma.
CL2012000447A1 (es) Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica.
Wang et al. Generation of a live attenuated influenza vaccine that elicits broad protection in mice and ferrets
MX2017000014A (es) Metodo para producir acido graso de cadena media con el uso de beta-cetoacil-proteina portadora de acilo (acp) sintasa.
MX2013003470A (es) Estructuras de consenso de antigenos y vacunas elaboradas a partir de estas y metodos para utilizarlas en el tratamiento de la malaria.
WO2023094713A2 (en) Coronavirus vaccine
MX2023000041A (es) Composiciones y metodos para inducir una respuesta inmunitaria contra coronavirus.
Gergen et al. mRNA-based vaccines and mode of action
MX2023000881A (es) Estructura genomica del virus de la influenza.
WO2022103929A3 (en) Nucleic acids, proteins, and vaccines of sars-cov-2
AR110626A1 (es) Paramixovirus y sus usos